Pace of Monjuvi’s growth may dictate how quickly MorphoSys can rebuild its pipeline

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the cash flows needed to rebuild MorphoSys’ early-stage pipeline. 

According to CEO Jean-Paul Kress, the near-term future and value of MorphoSys AG (Xetra:MOR; NASDAQ:MOR) are inextricably tied to the potential of Monjuvi tafasitimab-cxix in a range of hematologic cancers...